Avanza Fonder AB Takes $2.75 Million Position in IQVIA Holdings Inc. (NYSE:IQV)

Avanza Fonder AB bought a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) during the fourth quarter, HoldingsChannel reports. The institutional investor bought 13,971 shares of the medical research company’s stock, valued at approximately $2,745,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Private Trust Co. NA raised its holdings in shares of IQVIA by 10.7% in the 3rd quarter. Private Trust Co. NA now owns 485 shares of the medical research company’s stock worth $115,000 after purchasing an additional 47 shares in the last quarter. Clear Harbor Asset Management LLC increased its holdings in shares of IQVIA by 1.3% in the third quarter. Clear Harbor Asset Management LLC now owns 3,969 shares of the medical research company’s stock valued at $941,000 after buying an additional 50 shares in the last quarter. Pine Valley Investments Ltd Liability Co boosted its stake in shares of IQVIA by 0.5% during the 3rd quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company’s stock worth $2,247,000 after acquiring an additional 50 shares in the last quarter. Fortitude Family Office LLC grew its holdings in shares of IQVIA by 2.9% in the 3rd quarter. Fortitude Family Office LLC now owns 1,977 shares of the medical research company’s stock worth $468,000 after acquiring an additional 56 shares during the last quarter. Finally, Huntington National Bank raised its position in shares of IQVIA by 7.4% during the third quarter. Huntington National Bank now owns 809 shares of the medical research company’s stock worth $192,000 after purchasing an additional 56 shares during the period. 89.62% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the company. William Blair reissued an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th. Royal Bank of Canada restated an “outperform” rating and set a $270.00 price target on shares of IQVIA in a report on Wednesday, December 11th. The Goldman Sachs Group decreased their price objective on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Bank of America cut their target price on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. Finally, Barclays lowered their price target on IQVIA from $260.00 to $255.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Four investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $255.82.

IQVIA Price Performance

Shares of IQV opened at $197.25 on Friday. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. The firm has a market cap of $35.80 billion, a PE ratio of 25.89, a PEG ratio of 2.09 and a beta of 1.48. The firm’s 50 day moving average price is $200.09 and its 200 day moving average price is $221.19. IQVIA Holdings Inc. has a twelve month low of $187.62 and a twelve month high of $261.73.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.